Abstract 16P
Background
Peritoneal metastasis is a relatively common manifestation of poor prognosis and resistance to immune checkpoint blockades in patients with gastric cancer (GC). In the present study, we aimed to investigate the exhaustion status of CD8+ T cells and immunosuppressive soluble factors in malignant ascites from patients with GC and peritoneal metastasis.
Methods
We obtained pathologically confirmed malignant ascites samples along with peripheral blood from 27 patients with GC peritoneal metastasis and examined the exhaustion status of CD8+ T cells using multicolor flow cytometry. A multiplex enzyme-linked immunosorbent assay for immunosuppressive soluble factors, including matrix metalloproteinase-2 (MMP-2), MMP-7, transforming growth factor beta (TGF-β), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), E-cadherin, and angiopoietin-2, was performed on 45 cell-free fluid samples (15 paired malignant ascites and plasma of patients with GC and 15 benign ascites of liver cirrhosis patients).
Results
CD8+ T cells in the malignant ascites of GC showed significantly increased expression of PD-1, TIGIT, and TIM-3 compared with peripheral blood CD8+ T cells. CD8+ T-cells in malignant ascites had more terminally differentiated phenotypes (T-betlowEomeshigh) and tumor antigen reactivity (CD39+ CD103+) than peripheral blood CD8+ T cells. The expression levels of immunosuppressive soluble factors, including MMP-2, MMP-7, TGF-β, HGF, VEGF, E-cadherin, and angiopoietin-2, were significantly higher in the malignant ascites than in the plasma of patients with GC or in the benign ascites of liver cirrhosis patients.
Conclusions
We found that CD8+ T cells in the malignant ascites of GC are terminally exhausted and tumor antigen-reactive T cells. Furthermore, immunosuppressive soluble factors were significantly increased in cell-free fluid of malignant ascites of GC. Thus, the present findings suggest that the co-blockade of immune checkpoints and immunosuppressive soluble factors may be a feasible therapeutic option for patients GC with peritoneal metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09